Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

Excerpts from the latest filed MD&A:

Algernon Pharmaceuticals Inc.
MANAGEMENT’S DISCUSSION AND ANALYSIS
For the six months ended February 28, 2023
Dated April 28, 2023

1) Marketing expenses were $887,458 for the six months ended February 28, 2023 (2022 – $266,965). The increase from the six months ended February 28, 2022 resulted from additional marketing activities being performed during the six months ended February 28, 2023, including the Company being the headline sponsor for the 2022 Wonderland Psychedelic Conference in November 2022. Additional promotional activities were performed during the six months ended February 28, 2023.

2) LIQUIDITY AND CAPITAL RESOURCES

Liquidity risk is the risk that the Company will encounter difficulty in satisfying financial obligations as they become due. The Company manages its liquidity risk by forecasting cash flows from operations and anticipated investing and financing activities. The Company’s objective in managing liquidity risk is to maintain sufficient readily available reserves in order to meet its liquidity requirements.

At February 28, 2023, the Company had a working capital deficit of $1,970,610 compared to working capital at August 31, 2022 of $310,999. This included cash and cash equivalents of $220,585 (August 31, 2022 - $1,408,509) available to meet short-term business requirements and current liabilities of $2,447,732 (August 31, 2022 - $2,516,099). The Company’s accounts payable and accrued liabilities have contractual maturities of less than 30 days and are subject to normal trade terms. The Company has no long-term debt.

At present, the Company has no current operating income. The Company will need to raise sufficient working capital to maintain operations. Without additional financing, the Company may not be able to fund its ongoing operations and complete development activities. The Company intends to finance its future requirements through a combination of debt and/or equity issuance. There is no assurance that the company will be able to obtain such financings or obtain them on favourable terms. These uncertainties may cast doubt on the Company’s ability to continue as a going concern.

Full stop

Ya Think The Decision To Continue Prancing Around Penny Land Like A Peacock With Your "Marketing" Money Is Worthy Of A Feather In The CEO's Cap? Monies You Clearly Do Not Have To Waste That's Targeted At Propping Up The "Privately" Traded Subsidiary AGN Neuro?



Any Of You Own Direct Shares Of AGN Neuro or Just Sitting On The Sidelines Hoping Yet Another Disaster Does Not Unfolded To The Tune Of 90% Plus Losses Across The Checker Board?

Meanwhile, Companies Like Bellus Health (NASDAQ: BLU), Bellus Health Was Recently A Two Billion Dollar Buyout Pharma Company That CEO Moreau Has Long Since Tried Tieing A "Competitive Comparison" To It And AGN/PF, Remained Low Key And Data Driven For It's Shareholders. Bellus Health Continue To Be One To Watch As A Lesson On How To Run A Successful And Expeditious Standalone Clinical Trials In The USA Without The Need For Paltry "Tax Rebates" Long After Data Results. The Australian (Land Down Under/Dante's Inferno/Hurry Up And Wait/Purgatory) Clinical Trial angle, IF Chosen Once Again As Part Of A Miserable Marketing Message - "Multinational" Clinical Trial Of It's IFENPRODIL Chronic Cough Angle, And It Will Most Likely Be Yet Another Powergun Nail In The Coffin For Parent Company - Algernon Pharmaceuticals Inc.

Thus, Maybe You should Seriously Consider Buying Direct Shares Of AGN Neuro? It Could Soon Become Your Last Gasp At Recouping Massive Losses From The COVID-19 Era Moving Forward >>>

M$

Outro